menu
    • menu
    [{"orgOrder":0,"company":"Silvanols","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olea Europea Extract","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ Inapplicable"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Lorraine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"LATVIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crocus Sativus","moa":"||GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ University of Lorraine","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ University of Lorraine"},{"orgOrder":0,"company":"Silvanols","sponsor":"University of Latvia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Olea Europea","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Silvanols","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Silvanols \/ University of Latvia","highestDevelopmentStatusID":"15","companyTruncated":"Silvanols \/ University of Latvia"},{"orgOrder":0,"company":"Olpha","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LATVIA","productType":"Antibiotic","year":"2021","type":"Agreement","leadProduct":"Furazidin","moa":"Bacterial ribosome","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Olpha","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olpha \/ Adalvo","highestDevelopmentStatusID":"15","companyTruncated":"Olpha \/ Adalvo"}]

    Find Clinical Drug Pipeline Developments & Deals by Olpha

    Menu

    Olpha

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Olpha

    Latvia
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothOlpha, a JSC AB City subsidiary, is a leading Baltic firm with 50 years of experience in medicines & chemical pharmaceuticals.

    Lead Product(s) : Furazidin

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Adalvo

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    JSC Olainfarm & Adalvo to Launch a New Urology Product in 17 Countries In 2022-2023

    Details : In partnership Olainfarm will manage Furagins (Furaginum) regulatory affairs, distribution and promotion in Latvia, Russia, Kazakhstan, Belarus, Ukraine, and other countries and Adalvo will be responsible for development, manufacturing and will support m...

    Product Name : Furagins

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    June 16, 2021

    Lead Product(s) : Furazidin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Adalvo

    Deal Size : Undisclosed

    Deal Type : Agreement

    Olpha

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Silvanols

    Latvia
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tabebuia Avellandae Extract,Olea Europea,Zinc Glycinate

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : University of Latvia

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Latvia Can! A New Remedy for Respiratory Diseases Created and Researched!

    Details : Goimmune Strong contains bark extract of pink tabebuia, olive leaf extract, brazilian green propolis, zinc bisglycinate and organic selenium. It promotes the protection of cells against oxidative stress and showed antibacterial activity in respiratory di...

    Product Name : Goimmune Strong

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 02, 2021

    Lead Product(s) : Tabebuia Avellandae Extract,Olea Europea,Zinc Glycinate

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : University of Latvia

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    Silvanols

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Silvanols

    Latvia
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Lactium,Crocus Sativus,Ginseng Extract

    Therapeutic Area : Psychiatry/Psychology

    Study Phase : Approved FDF

    Sponsor : University of Lorraine

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Silvanols Launches the First Combined Product in Latvia with The Innovative Ingredient Lactium® – Against E...

    Details : GoRelax (lactium), specially patented cow’s milk protein split, has shown that this rotein improves sleep and is a natural anti-anxiety agent that helps reduce signs of stress.

    Product Name : GoRelax Day

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    March 26, 2020

    Lead Product(s) : Lactium,Crocus Sativus,Ginseng Extract

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Sponsor : University of Lorraine

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    Silvanols

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Silvanols

    Latvia
    Pharma Live Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tabebuia Avellandae Extract,Olea Europea Extract,Zinc Glycinate

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Silvanols Puts Special Emphasis on A Research-Based and Developed Agent to Strengthen the Body’s Defence Abi...

    Details : GoImmune STRONG (tabebuia avellandae extract), a unique remedy for the season of the common cold, which includes green propolis, tabebuia bark and olive leaf extracts, as well as zinc and selenium.

    Product Name : GoImmune STRONG

    Product Type : Other Small Molecule

    Upfront Cash : Inapplicable

    February 28, 2020

    Lead Product(s) : Tabebuia Avellandae Extract,Olea Europea Extract,Zinc Glycinate

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    Silvanols

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth